Ecnoglutide Approved in China: A New GLP-1 Breakthrough For Weight Loss

A new generation of GLP-1 receptor agonist has officially entered the market.
Ecnoglutide, the world's first cAMP-biased GLP-1 drug, has been approved in China for long-term weight management in adults with overweight or obesity.

With clinical data showing up to 15.4% weight loss over 48 weeks, this innovative therapy is drawing strong attention as a potential competitor to leading drugs such as Semaglutide and Tirzepatide.

 

What Is Ecnoglutide?

Ecnoglutide is a novel GLP-1 receptor agonist developed by a Chinese biotech company, representing a new class of cAMP-biased GLP-1 therapies.

Unlike traditional GLP-1 drugs, which activate multiple intracellular signaling pathways, Ecnoglutide selectively targets the cAMP signaling pathway. This "biased agonism" may allow for:

Enhanced metabolic effects

More efficient weight reduction

Potentially improved tolerability

This mechanism positions Ecnoglutide as a next-generation optimization rather than a simple alternative to existing GLP-1 therapies.

 

Clinical Trial Results 

The approval of Ecnoglutide for weight management is based on a Phase III clinical trial conducted in overweight and obese adults in China.

Key Outcomes at 48 Weeks:

Average weight loss: 15.4% (placebo-adjusted: 15.1%)

≥5% weight loss: 92.8% of participants

≥10% weight loss: 79.6%

≥15% weight loss: 63.5%

Notably, patients continued to lose weight at the end of the 48-week treatment period, suggesting that longer treatment duration may yield even greater results.

 

Metabolic and Cardiovascular Benefits

Beyond weight reduction, Ecnoglutide demonstrated significant improvements in multiple cardiometabolic markers:

Reduced waist circumference

Lower blood pressure

Improved lipid profile

Decreased HbA1c and fasting glucose

Improved insulin sensitivity (HOMA-IR)

Additionally, serum uric acid levels decreased significantly, with a lower incidence of hyperuricemia compared to placebo.

 

Ecnoglutide vs Semaglutide Vs Tirzepatide

Drug	Mechanism	Average Weight Loss
Semaglutide	GLP-1 agonist	~12–15%
Tirzepatide	GLP-1 + GIP dual agonist	~20%
Ecnoglutide	cAMP-biased GLP-1	~15.4%

 

Ecnoglutide delivers competitive efficacy compared to leading GLP-1 drugs, outperforming many traditional GLP-1 agonists and approaching the performance of dual agonists.

 

Strategic Partnership with Pfizer

In February 2026, Pfizer entered a nearly $500 million agreement with the developer of Ecnoglutide, securing exclusive commercialization rights in mainland China.

This partnership signals strong confidence in the drug's commercial potential and scalability, indicating that Ecnoglutide is likely to become a major player in the obesity and diabetes markets.

 

Why This Matters for the Global Peptide Market

Ecnoglutide represents a significant milestone:

First approved cAMP-biased GLP-1 receptor agonist

Strong clinical efficacy in a large population

Backed by global pharmaceutical commercialization

Importantly, as a domestically developed therapy, it may also benefit from cost advantages and scalable manufacturing, making it a potentially attractive option in the global market.

 

Future Outlook

With dual indications for weight management and type 2 diabetes, Ecnoglutide is positioned to expand rapidly in both clinical and commercial settings.

As GLP-1-based therapies continue to evolve, innovations such as biased agonism could define the next wave of peptide drug development.

 

About Peptide Sourcing and Development

As demand for advanced peptide-based therapies grows, access to high-quality peptide synthesis, intermediates, and research compounds becomes increasingly critical.

Companies operating in the global peptide supply chain play a key role in supporting:

Drug development pipelines

Clinical research

Commercial-scale production

For partners seeking reliable peptide sourcing and customized solutions, working with experienced manufacturers ensures both quality consistency and supply stability.

 

Hottags:

Ecnoglutide, GLP-1 weight loss drug, cAMP biased GLP-1, obesity treatment 2026, Tirzepatide alternative, peptide weight loss therapy, GLP-1 peptide supplier